vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $108.5M, roughly 1.1× AMBARELLA INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -13.9%, a 17.2% gap on every dollar of revenue. On growth, AMBARELLA INC posted the faster year-over-year revenue change (31.2% vs 4.7%). AMBARELLA INC produced more free cash flow last quarter ($31.4M vs $7.6M). Over the past eight quarters, AMBARELLA INC's revenue compounded faster (45.0% CAGR vs 5.6%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
AMBA vs NATR — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $123.8M |
| Net Profit | $-15.1M | $4.1M |
| Gross Margin | 59.6% | 72.5% |
| Operating Margin | -15.0% | 4.3% |
| Net Margin | -13.9% | 3.3% |
| Revenue YoY | 31.2% | 4.7% |
| Net Profit YoY | 37.2% | 1379.4% |
| EPS (diluted) | $-0.35 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | $123.8M | ||
| Q3 25 | $95.5M | $128.3M | ||
| Q2 25 | $85.9M | $114.8M | ||
| Q1 25 | $84.0M | $113.2M | ||
| Q4 24 | $82.7M | $118.2M | ||
| Q3 24 | $63.7M | $114.6M | ||
| Q2 24 | $54.5M | $110.6M | ||
| Q1 24 | $51.6M | $111.0M |
| Q4 25 | $-15.1M | $4.1M | ||
| Q3 25 | $-20.0M | $5.3M | ||
| Q2 25 | $-24.3M | $5.3M | ||
| Q1 25 | $-20.2M | $4.7M | ||
| Q4 24 | $-24.1M | $-321.0K | ||
| Q3 24 | $-34.9M | $4.3M | ||
| Q2 24 | $-37.9M | $1.3M | ||
| Q1 24 | $-60.6M | $2.3M |
| Q4 25 | 59.6% | 72.5% | ||
| Q3 25 | 58.9% | 73.3% | ||
| Q2 25 | 60.0% | 71.7% | ||
| Q1 25 | 60.0% | 72.1% | ||
| Q4 24 | 60.6% | 72.0% | ||
| Q3 24 | 60.8% | 71.3% | ||
| Q2 24 | 60.9% | 71.4% | ||
| Q1 24 | 59.8% | 71.2% |
| Q4 25 | -15.0% | 4.3% | ||
| Q3 25 | -23.0% | 7.0% | ||
| Q2 25 | -30.1% | 3.7% | ||
| Q1 25 | -30.2% | 5.4% | ||
| Q4 24 | -30.9% | 3.8% | ||
| Q3 24 | -56.9% | 4.6% | ||
| Q2 24 | -72.4% | 5.1% | ||
| Q1 24 | -80.8% | 4.2% |
| Q4 25 | -13.9% | 3.3% | ||
| Q3 25 | -20.9% | 4.2% | ||
| Q2 25 | -28.3% | 4.6% | ||
| Q1 25 | -24.1% | 4.2% | ||
| Q4 24 | -29.1% | -0.3% | ||
| Q3 24 | -54.8% | 3.8% | ||
| Q2 24 | -69.6% | 1.2% | ||
| Q1 24 | -117.4% | 2.1% |
| Q4 25 | $-0.35 | $0.23 | ||
| Q3 25 | $-0.47 | $0.30 | ||
| Q2 25 | $-0.58 | $0.28 | ||
| Q1 25 | $-0.48 | $0.25 | ||
| Q4 24 | $-0.58 | $-0.02 | ||
| Q3 24 | $-0.85 | $0.23 | ||
| Q2 24 | $-0.93 | $0.07 | ||
| Q1 24 | $-1.51 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $590.1M | $161.6M |
| Total Assets | $751.9M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | $93.9M | ||
| Q3 25 | $142.7M | $95.6M | ||
| Q2 25 | $141.3M | $81.3M | ||
| Q1 25 | $144.6M | $86.5M | ||
| Q4 24 | $127.1M | $84.7M | ||
| Q3 24 | $153.9M | $78.7M | ||
| Q2 24 | $131.8M | $68.7M | ||
| Q1 24 | $144.9M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $590.1M | $161.6M | ||
| Q3 25 | $576.5M | $166.7M | ||
| Q2 25 | $572.7M | $163.7M | ||
| Q1 25 | $561.4M | $167.1M | ||
| Q4 24 | $554.3M | $161.0M | ||
| Q3 24 | $547.6M | $162.6M | ||
| Q2 24 | $555.4M | $156.4M | ||
| Q1 24 | $559.9M | $159.7M |
| Q4 25 | $751.9M | $261.1M | ||
| Q3 25 | $706.4M | $264.8M | ||
| Q2 25 | $701.9M | $254.9M | ||
| Q1 25 | $689.0M | $252.7M | ||
| Q4 24 | $670.8M | $240.9M | ||
| Q3 24 | $650.3M | $245.3M | ||
| Q2 24 | $638.7M | $235.8M | ||
| Q1 24 | $657.7M | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $9.9M |
| Free Cash FlowOCF − Capex | $31.4M | $7.6M |
| FCF MarginFCF / Revenue | 29.0% | 6.1% |
| Capex IntensityCapex / Revenue | 2.7% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | $9.9M | ||
| Q3 25 | $5.5M | $18.5M | ||
| Q2 25 | $14.8M | $4.3M | ||
| Q1 25 | $25.4M | $2.6M | ||
| Q4 24 | $6.6M | $12.2M | ||
| Q3 24 | $16.7M | $9.6M | ||
| Q2 24 | $-15.0M | $1.3M | ||
| Q1 24 | $-4.0M | $2.2M |
| Q4 25 | $31.4M | $7.6M | ||
| Q3 25 | $1.4M | $16.8M | ||
| Q2 25 | $10.2M | $3.0M | ||
| Q1 25 | $21.2M | $1.5M | ||
| Q4 24 | $4.1M | $10.0M | ||
| Q3 24 | $14.2M | $7.9M | ||
| Q2 24 | $-16.1M | $-2.0M | ||
| Q1 24 | $-6.0M | $-1.5M |
| Q4 25 | 29.0% | 6.1% | ||
| Q3 25 | 1.4% | 13.1% | ||
| Q2 25 | 11.9% | 2.6% | ||
| Q1 25 | 25.3% | 1.3% | ||
| Q4 24 | 5.0% | 8.5% | ||
| Q3 24 | 22.2% | 6.9% | ||
| Q2 24 | -29.5% | -1.9% | ||
| Q1 24 | -11.6% | -1.4% |
| Q4 25 | 2.7% | 1.9% | ||
| Q3 25 | 4.3% | 1.3% | ||
| Q2 25 | 5.3% | 1.2% | ||
| Q1 25 | 5.0% | 1.0% | ||
| Q4 24 | 3.0% | 1.9% | ||
| Q3 24 | 4.0% | 1.5% | ||
| Q2 24 | 2.1% | 3.0% | ||
| Q1 24 | 3.7% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
